Recursion completes Exscientia acquisition; pro forma shows increased net losses

RECURSION PHARMACEUTICALS, INC.

Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
Pro forma 2023 net loss of $548.7M ($1.74/share) vs Recursion standalone $328.1M.
Pro forma 9M 2024 net loss of $476.5M ($1.32/share) vs Recursion standalone $284.8M.
Combined total assets ~$1.55B, equity ~$1.14B as of Sept 30, 2024.
Goodwill of $76.9M and intangible assets of $355.1M recorded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.